CIP2A and bronchiolitis obliterans syndrome: Finally, a recent article observed that CIP2A expression was enhanced in a 2,3-butanedione-induced rat model of bronchiolitis obliterans, and treatment with ethoxysanguinarine reduced the CIP2A expression, intraluminal occlusion, inflammatory infiltration, and fibrosis [4].